Blue Oak is discovering and developing first-in-class therapeutics for brain disorders using a systems neurobiology strategy that designs privileged chemotypes to target brain circuitry and behavior. First-in-class drugs with new mechanisms-of-action are in late discovery phase for large unmet medical needs in bipolar disorder, schizophrenia and treatment resistant depression. Additionally, these compounds have the potential to identify novel pathways and targets for subsequent best-in-class drug discovery programs.